Home | UCB Medical Affairs

UCB dermatology medical affairs

UCB dermatology medical affairs

UCB is dedicated to the research and development of treatments for a wide array of skin disease. These diseases disrupt patients' lives, cause social stigma, physical pain, and severe discomfort. Our immunology research is centered around psoriasis, psoriatic arthritis, hidradenitis suppurativa, and other inflammatory conditions.

Plaque Psoriasis

Patients with plaque psoriasis (PSO) experience burden that is beyond skin deep. A number of observational studies and patient surveys show that not all patients with moderate-to-severe psoriasis are achieving clear skin, which can impact their quality of life.^1,2 Better understanding of the complex immunopathologic pathways in psoriasis is needed.

Learn More

Psoriatic  Arthritis

Psoriatic  Arthritis

Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic autoimmune inflammatory disease of the skin and musculoskeletal system characterized by systemic inflammation.³ The chronic inflammatory pathogenesis of PsA is complex and multifactorial, involving multiple adaptive and innate immune cells and pro-inflammatory cytokines.⁴ Deeper knowledge of PsA disease outcome measures is needed to understand why patients do not reach optimal outcomes.

Learn more

Hidradenitis Suppurativa

Hidradenitis Suppurativa

Hidradenitis Suppurativa

A chronic, recurrent, and debilitating inflammatory disease, hidradenitis suppurativa (HS) presents as painful bumps often located in areas with skin folds and is associated with multiple physical and psychosocial comorbidities.^5,6 HS is often misunderstood and misdiagnosed.⁷ Early diagnosis and medical intervention may slow progression of disease and help prevent patients from taking urgent measures to treat themselves. Current guidelines can assist healthcare providers in managing manifestations and severity of HS on a case-by-case basis.^8,9

Learn More

References

Armstrong A, Jarvis S, Boehncke W-H, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200-2207.
Gorelick J, Shrom D, Sikand K, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther (Heidelb). 2019;9(4):785-797.
Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423-441.
Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273-2284.
Okun MM, Flamm A, Werley EB, Kirby JS. Hidradenitis suppurativa: diagnosis and management in the emergency department. J Emerg Med. 2022;63(5):636-644.
Sabat R, Jemec GB, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):1-20.
Garg A, Neuren E, Cha D, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366-376.
Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91-101.
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644.